EPO approves Advaxis patent application for Listeria Antigens

Links shared publicly online about this topic.

1,477
total visits

EPO approves Advaxis patent application for Listeria Antigens

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has received notification from the European Patent Office (EPO) that Advaxis patent application 98957980.0 titled Bacterial Vaccines Comprising Auxotrophic, Attenuated Strains of Listeria Expressing Heterologous Antigens, has been granted and will be issued as patent #1032417

View full resource at news-medical.net

Tags: Vaccination, Cancer, Prostate Cancer, Prostate, Men's Health, Vaccine